All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

146

Reset

146 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • ADX-2191Phase 31 trial

    Aldeyra Therapeutics, Inc. · Primary Vitreoretinal Lymphoma

  • ATSN-201Phase 31 trial

    Atsena Therapeutics Inc. · X-linked Retinoschisis

  • AVT29proposed aflibercept HD biosimilarPhase 31 trial

    Alvotech Swiss AG · Diabetic Macular Edema

  • CAM-101Elate Ocular, FD hPLPhase 31 trial

    Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic

  • HLX04-OPhase 31 trial

    Shanghai Henlius Biotech · Age Related Macular Degeneration

  • Roche (Genentech) · Diabetic Macular Edema

  • licaminlimabPhase 31 trial

    Oculis · Dry Eye Disease (DED)

  • OCU410Phase 31 trial

    Ocugen · Dry Age-related Macular Degeneration

  • OPC-1085ELPhase 31 trial

    Otsuka · Open Angle Glaucoma or Ocular Hypertension

  • QL1207HPhase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Neovascular Age-Related Macular Degeneration (nAMD)

  • RC28-EPhase 31 trial

    RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD

  • REGN5713BremzalerbartPhase 31 trial

    Regeneron · Allergic Conjunctivitis

  • REGN5715AtisnolerbartPhase 31 trial

    Regeneron · Allergic Conjunctivitis

  • RTx-015Phase 31 trial

    Ray Therapeutics, Inc. · Retinitis Pigmentosa (RP), Inherited Retinal Diseases

  • SJP-0132Phase 31 trial

    Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. · Dry Eye

  • VVN001Phase 31 trial

    VivaVision Biotech, Inc · Dry Eye

  • AL-001lithium salicylate, L-proline cocrystalPhase 23 trials

    Beijing Anlong Biopharmaceutical Co., Ltd. · Wet Age-related Macular Degeneration (wAMD), Bipolar I Disorder

  • GenSci048Phase 23 trials

    Changchun GeneScience Pharmaceutical Co., Ltd. · Uveitis, Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)

  • QLS-111Phase 23 trials

    Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)

  • roginolisibIOA-244Phase 23 trials

    iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC

  • TL-925Phase 23 trials

    Telios Pharma, Inc. · Allergic Conjunctivitis, Allergic Conjunctivitis of Both Eyes

  • 0.25% RCI001RCI001Phase 22 trials

    ORA, Inc. · Dry Eye Disease (DED), Dry Eye

  • BGE-102Phase 22 trials

    BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk

  • BL1107Phase 22 trials

    Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma

  • BLU-808Phase 22 trials

    Blueprint Medicines Corporation · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis

  • BRIMOCHOL PF eye dropsCARBACHOL PF eye drops, Brimonidine tartrate eye dropsPhase 22 trials

    Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Presbyopia, Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive

  • BS01Phase 22 trials

    Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

  • Laboratoires Thea · Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind

  • KHK4951Phase 22 trials

    Kyowa Kirin Co., Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)

  • LASN01Phase 22 trials

    Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy

  • NT-101Phase 22 trials

    NexThera Co., Ltd. · Wet Age Related Macular Degeneration, Wet AMD

  • OpRegenPhase 22 trials

    Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy

  • Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma

  • Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma

  • rAAV2tYF-GRK1-RPGRPhase 22 trials

    Beacon Therapeutics · X-Linked Retinitis Pigmentosa

  • TTAX03Phase 22 trials

    BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis

  • ABBV-6628Phase 21 trial

    AbbVie · Geographic Atrophy, Age-Related Macular Degeneration

  • ACDN-01Phase 21 trial

    Ascidian Therapeutics, Inc · Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration

  • Beacon Therapeutics · X-Linked Retinitis Pigmentosa (XLRP)

  • AGN-193408Phase 21 trial

    AbbVie · Open-angle Glaucoma, Ocular Hypertension

  • AIV007Phase 21 trial

    AiViva BioPharma, Inc. · Neovascular (Wet) Age-Related Macular Degeneration

  • APL-3007Phase 21 trial

    Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • AR-17043Phase 21 trial

    Alcon Research · Open Angle Glaucoma, Ocular Hypertension

  • ASKG712AM712, VIS-101Phase 21 trial

    Visara, Inc. · Neovascular Age-related Macular Degeneration

  • ASP2767Phase 21 trial

    Astellas · Glaucoma

  • AVD-104Phase 21 trial

    Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration

  • BI 1815368Phase 21 trial

    Boehringer Ingelheim · Macular Edema

  • BI 3812465Phase 21 trial

    Boehringer Ingelheim · Diabetic Macular Edema

  • BI 764524Phase 21 trial

    Boehringer Ingelheim · Diabetic Retinopathy

  • BI 771716Phase 21 trial

    Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy

NewerPage 2 of 3Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.